LSTM Clinical Validation3 Sep 2020 13:31
we know on the 7th August we entered into a collaboration with LSTM:
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with the Liverpool School of Tropical Medicine ("LSTM") to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.
Under the terms of the collaboration, LSTM will carry out the clinical validation of the Avacta COVID-19 antigen rapid saliva test in their category 3 laboratories on patient samples. In addition to working with the UK government's CONDOR programme to provide Avacta with access to patient samples in the UK, the partnership with LSTM also provides the opportunity to access patient samples in Africa and South America. The higher prevalence of the disease in those regions means that samples for prospective clinical validation studies are more readily available which, if necessary, could be used to speed up the validation process.
Sir Al's comment on yesterday's RNS suggests to us that he knows he has smashed it:
Authorities around the world are now looking to carry-out frequent mass testing to identify the most infectious people promptly in order to reduce infection rates and combat the coronavirus pandemic. That requires a highly specific test to minimize false positives which would otherwise overwhelm healthcare systems. The Affimer reagents that we have generated are very specific to SARS-CoV-2 antigen and we are confident of meeting and exceeding the clinical performance requirements for identifying the most infectious people.
We also know that LSTM took 4 and a half weeks to validate a Mologic lateral flow antibody test.
They have had ours 4 weeks tomorrow so I would hope for some news next week they are probably under a lot of pressure from the government too and have to get this right.....
Sign In
Follow the stocks
